These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 31035945

  • 1. Plasma levels of M-CSF and VEGF in laboratory diagnostics and differentiation of selected histological types of cervical cancers.
    Sidorkiewicz I, Zbucka-Krętowska M, Zaręba K, Lubowicka E, Zajkowska M, Szmitkowski M, Gacuta E, Ławicki S.
    BMC Cancer; 2019 Apr 29; 19(1):398. PubMed ID: 31035945
    [Abstract] [Full Text] [Related]

  • 2. Plasma levels and diagnostic utility of macrophage-colony stimulating factor, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 as tumor markers in cervical cancer patients.
    Zajkowska M, Zbucka-Krętowska M, Sidorkiewicz I, Lubowicka E, Gacuta E, Szmitkowski M, Chrostek L, Ławicki S.
    Tumour Biol; 2018 Jul 29; 40(7):1010428318790363. PubMed ID: 30052166
    [Abstract] [Full Text] [Related]

  • 3. Human Plasma Levels of Vascular Endothelial Growth Factor, Matrix Metalloproteinase 9, and Tissue Inhibitor of Matrix Metalloproteinase 1 and Their Applicability as Tumor Markers in Diagnoses of Cervical Cancer Based on ROC Analysis.
    Zajkowska M, Zbucka-Krętowska M, Sidorkiewicz I, Lubowicka E, Będkowska GE, Gacuta E, Szmitkowski M, Ławicki S.
    Cancer Control; 2018 Jul 29; 25(1):1073274818789357. PubMed ID: 30037277
    [Abstract] [Full Text] [Related]

  • 4. Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis.
    Lubowicka E, Zbucka-Kretowska M, Sidorkiewicz I, Zajkowska M, Gacuta E, Puchnarewicz A, Chrostek L, Szmitkowski M, Ławicki S.
    Pathol Oncol Res; 2020 Apr 29; 26(2):791-800. PubMed ID: 30820752
    [Abstract] [Full Text] [Related]

  • 5. Pretreatment plasma levels and diagnostic utility of hematopoietic cytokines in cervical cancer or cervical intraepithelial neoplasia patients.
    Ławicki S, Będkowska GE, Gacuta-Szumarska E, Knapp P, Szmitkowski M.
    Folia Histochem Cytobiol; 2012 Jul 04; 50(2):213-9. PubMed ID: 22763962
    [Abstract] [Full Text] [Related]

  • 6. Squamous cell carcinoma antigen and cancer antigen 125 in southern Indian cervical cancer patients.
    Porika M, Vemunoori AK, Tippani R, Mohammad A, Bollam SR, Abbagani S.
    Asian Pac J Cancer Prev; 2010 Jul 04; 11(6):1745-7. PubMed ID: 21338226
    [Abstract] [Full Text] [Related]

  • 7. Plasma Levels and Tissue Expression of Selected Cytokines, Metalloproteinases and Tissue Inhibitors in Patients With Cervical Cancer.
    Sidorkiewicz I, Piskór B, Dąbrowska E, Guzińska-Ustymowicz K, Pryczynicz A, Zbucka-Krętowska M, Ławicki S.
    Anticancer Res; 2019 Nov 04; 39(11):6403-6412. PubMed ID: 31704874
    [Abstract] [Full Text] [Related]

  • 8. Clinical significance of serum macrophage-colony stimulating factor (M-CSF) in esophageal cancer patients and its comparison with classical tumor markers.
    Łukaszewicz-Zajac M, Mroczko B, Kozłowski M, Nikliński J, Laudański J, Szmitkowski M.
    Clin Chem Lab Med; 2010 Oct 04; 48(10):1467-73. PubMed ID: 20604722
    [Abstract] [Full Text] [Related]

  • 9. [The plasma levels and diagnostic utility of stem cell factor (SCF) and macrophage-colony stimulating factor (M-CSF) in cervical cancer patients].
    Lawicki S, Bedkowska E, Gacuta-Szumarska E, Knapp P, Szmitkowski M.
    Pol Merkur Lekarski; 2008 Jul 04; 25(145):38-42. PubMed ID: 18839612
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of serum human telomerase reverse transcriptase as a novel marker for cervical cancer.
    Porika M, Tippani R, Mohammad A, Bollam SR, Panuganti SD, Abbagani S.
    Int J Biol Markers; 2011 Jul 04; 26(1):22-6. PubMed ID: 21319134
    [Abstract] [Full Text] [Related]

  • 11. Serum expression level of squamous cell carcinoma antigen, highly sensitive C-reactive protein, and CA-125 as potential biomarkers for recurrence of cervical cancer.
    Guo S, Yang B, Liu H, Li Y, Li S, Ma L, Liu J, Guo W.
    J Cancer Res Ther; 2017 Jul 04; 13(4):689-692. PubMed ID: 28901315
    [Abstract] [Full Text] [Related]

  • 12. [Clinical significance of serum squamous cell carcinoma antigen in the diagnosis, treatment and prognosis of cervical squamous cell carcinoma].
    Luan XM, Zhang Y, Wang SZ, Wang N, Li W, Zhang Q, Wei H, Zhang SL.
    Zhonghua Yi Xue Za Zhi; 2012 May 22; 92(19):1330-3. PubMed ID: 22883121
    [Abstract] [Full Text] [Related]

  • 13. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
    Gadducci A, Tana R, Cosio S, Genazzani AR.
    Crit Rev Oncol Hematol; 2008 Apr 22; 66(1):10-20. PubMed ID: 17964182
    [Abstract] [Full Text] [Related]

  • 14. Plasma Levels and Diagnostic Utility of Macrophage Colony-Stimulating Factor, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinases-1 as New Biomarkers of Breast Cancer.
    Ławicki S, Głażewska EK, Sobolewska M, Będkowska GE, Szmitkowski M.
    Ann Lab Med; 2016 May 22; 36(3):223-9. PubMed ID: 26915610
    [Abstract] [Full Text] [Related]

  • 15. Clinical significance of serum CA-125 and soluble tumor necrosis factor receptor type I in cervical adenocarcinoma patients.
    Kotowicz B, Kaminska J, Fuksiewicz M, Kowalska M, Jonska-Gmyrek J, Gawrychowski K, Sobotkowski J, Skrzypczak M, Starzewski J, Bidzinski M.
    Int J Gynecol Cancer; 2010 May 22; 20(4):588-92. PubMed ID: 20686378
    [Abstract] [Full Text] [Related]

  • 16. Clinical value of tumor markers for early detection of recurrence in patients with cervical adenocarcinoma and adenosquamous carcinoma.
    Tabata T, Takeshima N, Tanaka N, Hirai Y, Hasumi K.
    Tumour Biol; 2000 May 22; 21(6):375-80. PubMed ID: 11006578
    [Abstract] [Full Text] [Related]

  • 17. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer.
    Davelaar EM, van de Lande J, von Mensdorff-Pouilly S, Blankenstein MA, Verheijen RH, Kenemans P.
    Tumour Biol; 2008 May 22; 29(1):9-17. PubMed ID: 18497544
    [Abstract] [Full Text] [Related]

  • 18. Application of tumor markers SCC-Ag, CEA, and TPA in patients with cervical precancerous lesions.
    Farzaneh F, Shahghassempour S, Noshine B, Arab M, Yaseri M, Rafizadeh M, Alizadeh K.
    Asian Pac J Cancer Prev; 2014 May 22; 15(9):3911-4. PubMed ID: 24935573
    [Abstract] [Full Text] [Related]

  • 19. [New tumour markers useful in diagnostics and monitoring of cervical cancer].
    Bedkowska GE, Lawicki S, Szmitkowski M.
    Przegl Lek; 2007 May 22; 64(12):1022-7. PubMed ID: 18595508
    [Abstract] [Full Text] [Related]

  • 20. [The plasma levels and diagnostic utility of stem cell factor and macrophage--colony stimulating factor in endometrial cancer patients].
    Lawicki S, Bedkowska E, Gacuta-Szumarska E, Czygier M, Szmitkowski M.
    Przegl Lek; 2007 May 22; 64(12):987-90. PubMed ID: 18595499
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.